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The activity of liver 6-phosphofructo-2-kinase (PFK-2), the enzyme that catalyses the synthesis of fructose 2,dbisphosphate, was markedly de- 
creased in hypothyroid rats and partially restored after 3 days of treatment with triiodothyronine. The changes in PFK-2 activity were accompanied 
by parallel changes in enzyme content measured by immunotitration and in PFK-2 mRNA determined by dot blot and Northern blot hybridization 
with cDNA probes. It is concluded that thyroid hormone stimulates liver PFK-2 gene expression by a pre-translational mechanism. 
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1. INTRODUCTION 
Fructose 2,4-bisphosphate is a potent stimulator of 
glycolysis in mammalian tissues. It mediates the 
stimulation of phosphofructokinase by hormonal and 
metabolic signals [l]. Its synthesis from fructose 
6-phosphate and ATP is catalyzed by (i-phospho- 
fructo-Zkinase (PFK-2; EC 2.7.1.105), which occurs in 
several isozymic forms [I], The liver (L) isozyme of 
PFK-2 is phosphorylated on Ser-32 by the cyclic AMP- 
dependent protein kinase and this covalent change de- 
creases PFK-2 activity. The muscle (M) isozyme does 
not contain this phosphorylation site. The mRNA for 
the M-isozyme is found in rat liver, but at a much lower 
concentration than the L-type mRNA [Z]. PFK-2 activi- 
ty is also regulated by translational and transcriptional 
mechanisms. In diabetic or starved rats liver PFK-2 
content, but not mRNA, is decreased [3], whereas with 
insulin injection or refeeding, respectively, PFK-2 con- 
tent and mRNA levels are increased [4]. Rat liver PFK-2 
activity decreases after adrenalectomy and is restored 
by glucocorticoid hormone replacement. This has been 
ascribed to altered rates of transcription of the PFK-2 
gene, resulting in changes in content of PFK-2 mRNA 
and protein [5]. Gualberto et al. [6] have reported de- 
creased PFK-2 activity in the heart of hypothyroid rats. 
We have recently developed antibody and cDNA probes 
for PFK-2 [3,7]. Since liver glycolysis is impaired in 
hypothyroid rats [8], we have now used these probes to 
examine the effect of thyroid status on liver PFK-2. 
2. EXPERIMENTAL 
Male Wistar rats (120 g) were made hypothyroid by feeding an 
iodine-deficient diet (25 cg iodine/kg food) @JAR, Villemoisson-sur- 
Orge, France) with a 1% NaC10.r solution as drinking water. Control 
rats were fed normal chow (diet no. A04 from UAR). After 40 days, 
control and hypothyroid rats were injected i.p. with vehicle (0.9% 
NaCl, 0.1% NaOH) or triiodothyronine (Ts) (Sigma; lO~g/1OO g
body wt per day) for 3 days at 10.00 h. They were killed by a Nem- 
butal injection at 14.00 h on the third day, followed by removal of the 
tissues. Livers and hearts were freeze-clamped in liquid nitrogen and 
blood samples were taken from the thoracic aorta. Liver samples 
(about 100 mg) were homogenized (Teflon-glass Potter) in 10 vols of 
an ice-cold buffer containing 50 mM KCl, 2 mM EDTA, 5 mM 
MgClz, 20 mM KF, 0.1 mM fructose &phosphate, 0.3 mM glucose 
6-phosphate, 1 mM dithiothreitol, 0.1 mM phenylmethyisulfonyl 
fluoride, 0.1 gg/ml of pepstatin, leupeptin, and aprotinin, and 
20 mM Hepes, pH 7.5. Cytosols were prepared by taking the super- 
nate after centrifugation at 100000 x g for 20 min. Liver PFK-2 was 
measured at 3O’C and pH 8.5. This gives the total activity, which is 
insensitive to the phosphorylation state of the enzyme 191. Heart 
PFK-2 activity, which is insensitive to cyclic AMP-dependent protein 
kinase, was measured at pH 7.1 [lo] in cytosols prepared as described 
for liver. immunotitra~on was carried out as described [3] using an 
antibody (BCL-2) raised against purified chicken liver PFK-2. 
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cDNA probes [2,7] specific for the L-type (22c2-Sau3A) and the M- 
type (ScS-DdeI) PFK-2 mRNA, and one common to both isozymes 
(22cl), were multiprime-labelled with [cu-‘2P]dCTP to a specific ac- 
tivity of 2-4 x 10’ cpm/pg. A chicken@-actin probe was also used as 
an internal control. Total RNA was extracted by a modified ill] 
guanidine thiocyanate method (121. Dot blot 1131 RNA-cDNA 
hybridi~tion was performed on RNA denatured with form- 
aldehyde/formamide, using prehybridization and hybridization con- 
ditions as described [3]. Filters were washed for 30 min at room 
temperature, then for two periods of 30 min at 50°C in 2 x SSC (SSC 
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is 0.15 M NaCl, 0.015 M Na citrate), 0.1% SDS. Intensity of 
hybridization was measured by counting the radioactivity of the RNA 
spots, with radioactivity of blank filter subtracted as background. For 
Northern blot analysis [2], total RNA was resuspended in a denatur- 
ing loading buffer, heat denatured, and electrophoresed [14] in the 
presence of 1 pglmi ethidium bromide. The gel was photographed 
under UV light to record migration of RNA molecular weight markers 
(BRL) and to monitor the quantity of RNA loaded by densitometry 
of 28 S and 18 S rRNA. RNA was transferred to a nylon membrane 
(Hybond N, Amersham) in 10 x SSC for at least 12 h, then fixed onto 
the membrane by UV irradiation for 5 min. Filters were prehybridiz- 
ed and hybridized as described [2] and washed twice in 200 ml 2 x 
SSC, 0.1% SDS for 30 min at room temperature, and then twice in 
200 ml 0.2 x SSC, 0.1% SDS for 30 mm at 50°C. Autoradiographs 
were scanned (Joyce-Loebl densitometer) and the values obtained 
were corrected for the amount of RNA loaded determined as describ- 
ed above. 
Serum thyroxine (T4) and T3 concentrations were determined by 
radioimmunoassay, with the Magic kit of Corning for Ts and the 
canine double antibody kit from Diagnostic Products Co. for Td. The 
latter can detect T4 concentrations below 1.25 pg/dl. Protein was 
measured [15] using bovine serum albumin as standard. Statistical 
analysis was carried out using Student’s r-test for unpaired data or 
Mann-Whitney U-test with significance level chosen as P<O.O5. 
3. RESULTS AND DISCUSSION 
3.1. Effect of the thyroid status on PFK-2 activity and 
content 
Serum levels of thyroid hormones were significantly 
decreased in hypothyroid versus control rats (table 1). 
Tj treatment normalized serum T4 levels in hypothyroid 
animals. Heart PFK-2 activity, whether expressed per 
mg of protein (table 1) or DNA (not shown), was not 
significantly decreased in hypoth~oid rats. The earlier 
demonstration [5] of decreased PFK-2 activity in hypo- 
thyroid rat heart may be related to the longer and more 
severe hypothyroid state of animals in that study. Liver 
PFK-2 activity in hypothyroid rats was about 25% of 
that in control rats (table 1). This reflects a decrease in 
total activity, and not simply an inactivation by phos- 
phorylation of the enzyme, since the activity was 
measured under conditions that are insensitive to the 
phosphorylation state of liver PFK-2. Total PFK-2 ac- 
tivity in hypothyroid animals was partially restored 
after 3 days of T3 treatment. There was no inhibitor of 
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Fig.1. lmmunotitration of liver PFK-2 measured as total activity re- 
maining after precipitation with the quantities of antiserum indicated. 
Cytosol protein concentration in the incubations (0.2 ml) was 
2 mg/ml. PFK-2 activity (&/rug protein) in absence of antiserum 
was 33.6 for the control, 9.3 for the hypothyroid, and 17.2 for the 
h~othyroid T,-treated rat. 
PFK-2 in hypothyroid rat liver since mixtures of liver 
cytosols from untreated and hypothyroid rats contained 
the expected PFK-2 activities. 
To determine whether these changes resulted from 
changes in enzyme content, PFK-2 was immunotitrated 
in the same liver samples. Representative immunotitra- 
tion curves are shown in fig.1. The decrease in total 
PFK-2 activity in liver from hypothyroid rats was ac- 
companied by a two-fold decrease in enzyme content. 
While PFK-2 activity was not completely restored by T3 
treatment in hypothyroid rats, enzyme content was nor- 
malized (fig.2). The discordance between PFK-2 activi- 
ty and content in these experiments uggests that the im- 
munotitrable enzyme was less active in hypothyroid 
than in normal rats, This defect was not corrected by T3 
and could depend on unknown factor(s) whose re- 
sponse to T3 treatment differs from that of PFK-2. 
Table 1 
Effect of hypothyroidism and T3 on thyroid hormones in serum and on PFK-2 activity 
Serum concentration PFK-2 activity f_&/mg protein) 
T4 @g/d11 Ts (ng/dl) Liver Heart 
Control (8) 5.36 f 0.47 68 f 4.0 28.4 k 1.9 7.86 f 2.2 
T3 (9) 4.21 + 0.33b 1290 + 30=-b 26.7 i 1.7 5.24 + 0.9 
Hypothyroid (9) 1.15 + 0.07” 25+ la 6.94 + 0.6a 4.00 + 0.6 
Hypothyroid + T3 (9) 7.29 f 0.36b 1500 Y!Z 12a.b 14.7 * 0.9a,b 5.22 + 0.5 
a Significantly different from untreated controls 
b Significantly different from untreated hypothyroid 
The values are means + SE for the number of animals given in parentheses 
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Fig.2. Effect of h~oth~oidism and T3 on PFK-2 activity (A), con- 
tent (B) and mRNA (C) in rat liver. PFK-2 content is expressed as ~1 
of antiserum required to precipitate 50% of the activity measured in 
absence of antiserum. Data were calculated from logit-log transfor- 
mations of plots such as those shown in fig. 1. Data for mRNA are 
from dot blot experiments uch as those in fig.3. For each RNA sam- 
ple the slope of the linear relationship between cpm hybridized andpg 
of RNA spotted was calculated for the PFK-2 probe (22~1) and for the 
actin probe. The ratio (X Id) of these slopes for each sample gave the 
values shown. Values are means + SEM for the number of animals 
shown in parentheses. (a) Significantly different from untreated con- 
trols; (b) significantly different from untreated hypothyroid rats. 
3.2. Effect of the thyroid status on liver PFK-2 mRNA 
To investigate the mechanism of decreased liver 
PFK-2 content in hypothyroid rats, we measured PFK-2 
mRNA with cDNA probes. Dot blot analysis of total 
liver RNA using probe 22~1 (fig.3) demonstrated that 
PFK-2 mRNA content of hypothyroid rat liver was 
about a third of that in control rats (fig.2). Ts treatment 
of hypothyroid rats resulted in an approximate 6-fold 
increase in PFK-2 mRNA, to a level greater than that 
seen in untreated controls. Northern blot analysis con- 
firmed that liver PFK-2 mRNA was indeed altered to 
the same extent as shown by dot blot (fig.4). Only one 
major hybridizing band at 2.1 kb (L-type mRNA) was 
seen with probe 22~1 under our experimental condi- 
tions. Since this probe is capable of hybridizing also 
with the 1.9 kb M-type mRNA [2], we conclude that the 
thyroid status did not shift the pattern of expression 
from the L-type towards the M-type mRNA. This was 
confirmed by dot blot analysis with the cDNA probe 
5c2-Ddel which is specific for the M-type mRNA. Vir- 
tually no signal could be detected with this probe on 
total liver RNA from any of the groups (not shown). 
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Fig.3. Dot blot hybridization of liver RNA with PFK-2 (22~1) and ac- 
tin cDNA probes. 
These data indicate that the L-type PFK-2 mRNA is 
specifically regulated by T3 through mRNA stabiliza- 
tion or (and) by a direct transcriptional effect. The lat- 
ter mechanism is consistent with the presence of 
nucleotide sequences containing putative thyroid hor- 
mone responsive elements in the 5 ’ flanking region of 
the PFK-2 gene [16]. In this study, T3 treatment of 
hypothyroid animals resulted in PFK-2 mRNA levels 
which were greater than those seen in controls, whereas 
enzyme content was restored only to control levels. This 
may be due to the turnover of PFK-2 being slower than 
that of its RNA [17]. Our results also suggest hat heart 
PFK-2 is less sensitive to hypothyroidism than liver 
Control Hypothyroid Hypothyroid 
\l/ :3 
Fig.4. Northern blot analysis of Iiver RNA hybridized to PFK-2 
cDNA probe 22~1. After 4 days of exposure, the 2.1-kb bands of the 
autoradiographs (a representative xperiment is shown in the inset) 
were scanned. The integrated area for each sample was corrected for 
total RNA loaded as described. Symbols are as in fig.2. 
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PFK-2. This may be related to the fact that the concen- 
tration of thyroid hormones in hypothyroid rats de- 
creases much more slowly over the weeks in heart tissue 
than in liver [ 181. The stimulation of liver lipogenesis by 
thyroid hormones might involve a higher provision of 
C-3 units through increased glycolysis [8]. The stimula- 
tion of PFK-2 gene expression by T3 described here is 
likely to contribute to this mechanism. 
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